CDC25B GENE PROMOTOR, AND PREPARATION AND USE THEREOF

    公开(公告)号:JPH11181A

    公开(公告)日:1999-01-06

    申请号:JP8499598

    申请日:1998-03-16

    Applicant: HOECHST AG

    Abstract: PROBLEM TO BE SOLVED: To obtain a new cdc25B gene promotor comprising a sequence capable of hybridizing with a specific base sequence or a functional part thereof under a stringent condition and useful for producing a nucleic acid-constructing substance for a gene therapy, etc. SOLUTION: This new cdc25B gene promotor comprises a sequence capable of hybridizing with a sequence expressed by the formula or a functional part thereof under a stringent condition, and is capable of binding with a structural gene of an enzyme, a fused protein, a cytokine, a chemokine, a growth factor, a receptor, an antibody, a vascular formation inhibitor, a peptide, a hormone, a coagulant, a fibrinolytic protein, etc., and useful for the production of a nucleic acid-structured substance for the gene for the gene therapy of a tumoral disease, leukemia, an autoimmune disease, an allergy, an arthritis, an organ transplant rejection, a blood coagulative disease, an infection, a hormonal disease, etc. The promotor is obtained by screening a mouse genome phage library obtained from a mouse family 129FVJ.

    POLYFUNCTIONAL LIGAND SYSTEM FOR CELL-SPECIFIC MIGRATION OF NUCLEIC ACID

    公开(公告)号:JPH11169A

    公开(公告)日:1999-01-06

    申请号:JP33050897

    申请日:1997-12-01

    Applicant: HOECHST AG

    Abstract: PROBLEM TO BE SOLVED: To obtain a polyfunctional ligand system that is not immnunogenic, can be readily prepared and used, and is useful as pharmaceuticals, by allowing the system to include a target cell-specific ligand and a (partially) antibody- containing gene structure-specific ligand. SOLUTION: The target cell-specific ligand linking to the cell surfaces of one or more target cells as growth factor, cytokine, interferon or the like and one or more gene constitution specific ligand including an antibody or its part as F(ab)2 fragment or the like are allowed to link to each other to prepare the objective polyfunctional ligand system containing synthetic fusion-induced peptide or cell fusion induced peptide, but it is not immunogenic. This ligand system is preferably used to produce a therapeutic and preventive drugs for skin diseases, mucous membrane diseases, neurosystem diseases, internal diseases and the like.

Patent Agency Ranking